Ads
related to: autoimmune disease that affects liver and spleen problems caused by smoking- Chronic GVHD Treatment
Learn About How a Medicine May
Be Able to Help.
- FAQs and Resources
Find Resources and Answers
to Frequently Asked Questions.
- For Chronic GVHD
Discover an Option That
May Help with Scarring and Swelling
- $0 Co-Pay
Learn How You Can Save on cGVHD
Treatment w/ our Co-Pay Program.
- Chronic GVHD Treatment
Search results
Results From The WOW.Com Content Network
Autoimmune hepatitis, formerly known as lupoid hepatitis, plasma cell hepatitis, or autoimmune chronic active hepatitis, is a chronic, autoimmune disease of the liver that occurs when the body's immune system attacks liver cells, causing the liver to be inflamed.
This article provides a list of autoimmune diseases. These conditions, where the body's immune system mistakenly attacks its own cells, affect a range of organs and systems within the body. Each disorder is listed with the primary organ or body part that it affects and the associated autoantibodies that are typically found in people diagnosed ...
The liver is enlarged (hepatomegaly) in 30–40% of patients. [citation needed] Autoimmune disease is the second most common clinical manifestation and one that most often requires treatment. The most common autoimmune presentations include autoimmune cytopenias, which can be mild to very severe and intermittent or chronic. [5]
Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver. [1] [2] [3] It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis.
Autoimmune diseases are very often treated with steroids. [3] Autoimmunity means presence of antibodies or T cells that react with self-protein and is present in all individuals, even in normal health state. It causes autoimmune diseases if self-reactivity can lead to tissue damage. [4]
This month, the FDA granted accelerated approval to Iqirvo (elafibranor) for the treatment of an autoimmune disease that can affect the liver called primary biliary cholangitis.